This patient wants to switch from an anti-CD20 therapy to oral cladribine in the hope that it is going to allow him to make an antibody response to the COVID-19 booster.
Thank you for this highly informative post. I understand the recommendation for waiting for some B cell recovery prior to starting cladribine. Do total lymphocyte counts need to be normal prior to switching? In realize this is part of the baseline assessment however I'm wondering about the risk of rebound activity in this interval. Also what if COVID vaccine boosters are not locally available yet at the time of a planned switch?
Fantastically well written. Thank you for the information...I have been planning a switch from OCR to Clad in the upcoming months myself. Any thoughts on any significant "upfront" BVL observations? Any thoughts on the relevancy of its effect on microglia or other CNS cells? Thanks again.
Thank you for this useful post.
Can we expect Cladribine to be as effective as anti-CD20? Or is it difficult to say?
Rituximab has been working well (12 courses in the last 10 years)
Would you need to wait some B cell recovery before moving from Ocrelizumab to Cladribine? Surprised this was not covered.
Thank you for this highly informative post. I understand the recommendation for waiting for some B cell recovery prior to starting cladribine. Do total lymphocyte counts need to be normal prior to switching? In realize this is part of the baseline assessment however I'm wondering about the risk of rebound activity in this interval. Also what if COVID vaccine boosters are not locally available yet at the time of a planned switch?
Fantastically well written. Thank you for the information...I have been planning a switch from OCR to Clad in the upcoming months myself. Any thoughts on any significant "upfront" BVL observations? Any thoughts on the relevancy of its effect on microglia or other CNS cells? Thanks again.
When you read this, especially that clad takes out 85-90% of Bcells, you wonder why anyone is on ocrelizumab anyway?